|
|
 Previous Article | Table of Contents | Next Article 
Expression of multidrug resistance P-glycoprotein on peripheral blood
mononuclear cells of patients with granular lymphocyte-proliferative
disorders
T Yamamoto, T Iwasaki, N Watanabe, K Oshimi, M Naito, T Tsuruo and Y Kobayashi
Department of Biomolecular Science, Faculty of Science, Toho University,
Chiba, Japan.
Some patients with granular lymphocyte-proliferative disorders (GLPD) have
been reported to have an aggressive clinical course with a poor prognosis
and to be refractory to chemotherapy. In this study, expression of
multidrug resistance P-glycoprotein on peripheral blood mononuclear cells
(PBMC) of 11 patients with GLPD was examined by staining with MRK 16, a
monoclonal antibody that binds to an external epitope of P-glycoprotein,
and with the dye rhodamine, a known substance to be excreted from the cells
through P-glycoprotein. Among those tested, the PBMC of six of eight
patients with T-cell-type GLPD as well as those of three of three patients
with natural killer cell- type GLPD expressed P-glycoprotein significantly.
Furthermore, PBMC of two of two patients were also poorly stained with the
dye rhodamine, and the treatment of PBMC with either verapamil or
quinidine, multidrug resistance-reversing agents, led to their increased
staining, suggesting that these PBMC actively release chemotherapeutic
agents.
Volume 81,
Issue 5,
pp. 1342-1346,
03/01/1993
Copyright © 1993 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Egashira, N. Kawamata, K. Sugimoto, T. Kaneko, and K. Oshimi
P-Glycoprotein Expression on Normal and Abnormally Expanded Natural Killer Cells and Inhibition of P-Glycoprotein Function by Cyclosporin A and Its Analogue, PSC833
Blood,
January 15, 1999;
93(2):
599 - 606.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. V. Srinivas, D. Middlemas, P. Flynn, and A. Fridland
Human Immunodeficiency Virus Protease Inhibitors Serve as Substrates for Multidrug Transporter Proteins MDR1 and MRP1 but Retain Antiviral Efficacy in Cell Lines Expressing These Transporters
Antimicrob. Agents Chemother.,
December 1, 1998;
42(12):
3157 - 3162.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
B. Drenou, T. Lamy, L. Amiot, O. Fardel, S. Caulet-Maugendre, M. Sasportes, J. Diebold, P.-Y. Le Prise, and R. Fauchet
CD3-CD56+ Non-Hodgkin's Lymphomas With an Aggressive Behavior Related to Multidrug Resistance
Blood,
April 15, 1997;
89(8):
2966 - 2974.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. W. Johnstone, K. M. Tainton, A. A. Ruefli, C. J. Froelich, L. Cerruti, S. M. Jane, and M. J. Smyth
P-glycoprotein Does Not Protect Cells against Cytolysis Induced by Pore-forming Proteins
J. Biol. Chem.,
May 11, 2001;
276(20):
16667 - 16673.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
